

# A randomised trial of a community pharmacist-initiated screening and intervention program for osteoporosis: the OsteoPharm Study

|  |   |  |
|--|---|--|
| <b>Submission date</b><br>04/11/2005   | <b>Recruitment status</b><br>No longer recruiting     | <input type="checkbox"/> Prospectively registered    |
| <b>Registration date</b><br>26/01/2006 | <b>Overall study status</b><br>Completed              | <input checked="" type="checkbox"/> Protocol         |
| <b>Last Edited</b><br>05/11/2008       | <b>Condition category</b><br>Musculoskeletal Diseases | <input type="checkbox"/> Statistical analysis plan   |
|  |   | <input type="checkbox"/> Results                     |
|  |   | <input type="checkbox"/> Individual participant data |
|  |   | <input type="checkbox"/> Record updated in last year |

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr Nese Yuksel

**Contact details**  
Faculty of Pharmacy and Pharmaceutical Sciences  
University of Alberta  
3126 Dentistry/Pharmacy Center  
Edmonton  
Canada  
T6R 2N6  
+1 780 492 4442  
nyuksel@pharmacy.ualberta.ca

## Additional identifiers

**Protocol serial number**  
186

## Study information

**Scientific Title**

**Acronym**

OsteoPharm

**Study objectives**

A community pharmacist-initiated multifaceted intervention will help increase the diagnosis and treatment of osteoporosis in patients at a high risk for fracture.

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Ethics approval received from the University of Alberta, Health Research Ethics Board-A on the 14th June 2005.

**Primary study design**

Interventional

**Study design**

Randomised, controlled multi-site trial with blinded ascertainment of outcomes

**Study type(s)**

Quality of life

**Health condition(s) or problem(s) studied**

Osteoporosis

**Interventions**

Intervention group:

Multifaceted interventions that consist of the following:

1. Screening by community pharmacists
2. Educational session on osteoporosis
3. Quantitative ultrasound (QUS) measurements
4. Referral to the primary care physician

Control group:

Usual care, defined as provision of generic pamphlet on osteoporosis.

Please note that as of 15/01/2008 the anticipated end date of this trial was extended to 30/09/2007. The previous end date of this trial was 01/10/2006.

**Intervention Type**

Other

**Phase**

Not Specified

**Primary outcome(s)**

Composite endpoint of the performance of a bone mineral density test or a new prescription for an osteoporosis medication within four months of study entry.

### **Key secondary outcome(s)**

1. Each component of the primary outcome
2. Use of calcium and vitamin D supplements
3. Patients osteoporosis related knowledge using the Facts on Osteoporosis Quiz, (FoOQ)
4. Changes in generic health status (RAND-12)
5. Osteoporosis specific quality of life

### **Completion date**

30/09/2007

## **Eligibility**

### **Key inclusion criteria**

Males or females who are:

1. Over the age of 50
2. Considered to be at a high risk for osteoporosis and fractures as defined by the Osteoporosis Society of Canada Clinical Practice guidelines and as defined specifically for the purposes of this study, i.e., are over the age of 65 years or between 50 - 64 years of age with any one of the following:
  - 2.1. Family history of osteoporosis
  - 2.2. Previous fragility fracture
  - 2.3. Systemic steroids
  - 2.4. Early menopause (for women)
3. Live in the Capital Health Region (Edmonton Region)

### **Participant type(s)**

Patient

### **Healthy volunteers allowed**

No

### **Age group**

Adult

### **Sex**

All

### **Key exclusion criteria**

1. Are unable or unwilling to provide informed consent
2. Are on current prescription treatment for osteoporosis
3. Have had a dual energy x-ray absorptiometry (DEXA) scan performed in the past two years
4. Are non-English speaking

### **Date of first enrolment**

16/11/2005

### **Date of final enrolment**

30/09/2007

# Locations

## Countries of recruitment

Canada

## Study participating centre

Faculty of Pharmacy and Pharmaceutical Sciences

Edmonton

Canada

T6R 2N6

# Sponsor information

## Organisation

University of Alberta (Canada)

## ROR

<https://ror.org/0160cpw27>

# Funder(s)

## Funder type

Charity

## Funder Name

Institute of Health Economics (IHE) (Canada) (account number: 186)

# Results and Publications

## Individual participant data (IPD) sharing plan

## IPD sharing plan summary

Not provided at time of registration

## Study outputs

| Output type                      | Details       | Date created | Date added | Peer reviewed? | Patient-facing? |
|----------------------------------|---------------|--------------|------------|----------------|-----------------|
| <a href="#">Protocol article</a> | protocol      | 01/03/2006   |            | Yes            | No              |
| <a href="#">Study website</a>    | Study website | 11/11/2025   | 11/11/2025 | No             | Yes             |

